Nkarta Inc represents a strong set of values and corporate philosophy. As a biotechnology company, Nkarta Inc is committed to transforming the lives of patients with complex diseases by harnessing the power of natural killer (NK) cells. The company believes in scientific innovation and collaboration to develop groundbreaking therapies. Nkarta Inc is devoted to delivering effective and safe treatments while maintaining the highest ethical standards. With a passion for improving patient outcomes, Nkarta Inc strives to be a leader in the biotech industry by driving advancements in cell therapy.

Nkarta Inc is primarily present in the United States.

Nkarta Inc, a leading biotechnology company, has achieved several significant milestones. Firstly, they successfully completed their IPO in 2020, raising substantial capital to fund their ongoing research and development efforts. Additionally, Nkarta has made remarkable progress in advancing their pipeline of novel natural killer (NK) cell therapies. They have received clearance from the FDA for their Investigational New Drug (IND) application, allowing them to initiate clinical trials. Nkarta has also forged strategic collaborations with renowned institutions, further reinforcing their expertise and expanding their reach in the field of cell therapies. These milestones demonstrate Nkarta Inc's commitment to revolutionizing cancer treatment through innovative therapies harnessing the power of NK cells.

Nkarta Inc, a biotechnology company founded in 2015, focuses on developing cellular therapies for cancer treatment. With headquarters in South San Francisco, California, Nkarta operates with a vision to harness the power of the body's immune system to combat cancer effectively. The company specializes in natural killer (NK) cells, which play a crucial role in protecting against tumor growth. Leveraging their proprietary technology, Nkarta engineers enhanced NK cells, known as NKT cells, to enhance their potency and persistence. As a prominent player in the field of cellular immunotherapy, Nkarta Inc strives to advance innovative treatments and improve outcomes for patients battling various cancers.

The main competitors of Nkarta Inc in the market are Adaptimmune Therapeutics, bluebird bio, and Celgene Corporation.

Nkarta Inc is primarily active in the biotechnology industry.

Nkarta Inc is a biotechnology company specializing in the development of cell therapies to treat cancer. The company's business model revolves around advancing its proprietary natural killer (NK) cell therapies. Nkarta Inc focuses on developing and commercializing off-the-shelf treatments that harness the power of the body's immune system to eliminate tumors. By genetically engineering and enhancing NK cells to target and kill cancer cells, Nkarta Inc aims to provide effective and accessible treatments for patients. As a leading player in the field of cell therapy, Nkarta Inc is committed to revolutionizing cancer treatment through its innovative business model.

De Nkarta K/W is -2,67.

De Nkarta KUV is 0.

De AlleAktien Kwaliteitsscore voor Nkarta is 2/10.

De omzet kan momenteel niet worden berekend voor Nkarta.

De verwachte Nkarta winst is -117,79 mln. USD.

Nkarta Inc is a biotechnology company specializing in developing innovative and personalized therapies for cancer patients based on natural killer cells (NK cells). The company has a business model that spans multiple sectors and offers a wide range of products and services. The first sector of Nkarta is the research and development of personalized NK cell therapies for cancer patients. NK cells are part of the innate immune system and can directly attack and kill cancer cells. Nkarta utilizes advanced technologies such as CRISPR/Cas9 genome editing and CAR (chimeric antigen receptor)-based NK cell therapies to enhance the effectiveness of NK cells. The company is working on developing therapies for various types of cancer, including leukemia, lymphoma, and solid tumors. The second sector of Nkarta is the manufacturing and provision of NK cell products for clinical studies. Nkarta has its own production facility that is GMP certified and meets the highest quality standards. The company offers customers a wide range of products such as natural killer cells (NK cells) obtained from the patient's blood or donor blood, CAR NK cells, as well as specialized devices and consumables. The third sector of Nkarta is collaboration with other companies and institutions in the development of personalized NK cell therapies. Nkarta works with various partners to accelerate the development of NK cell therapies and improve the effectiveness of NK cells in cancer therapy. The company recently partnered with CRISPR Therapeutics to further develop its CAR NK cell technology and conduct clinical studies. In addition to these sectors, Nkarta is also active in the field of financing. The company has conducted several funding rounds, raising over $100 million. These funds are used to finance research and development, manufacturing of NK cell products, and expansion of business operations. In summary, Nkarta offers a wide range of products and services in the field of personalized NK cell therapy. The company has a comprehensive business model that spans multiple sectors, including research and development, manufacturing of NK cell products, collaboration with partners, and financing. Thanks to its innovative technologies and highly skilled employees, Nkarta is well-positioned to offer its customers effective and personalized cancer treatment.

Nkarta keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Nkarta of het bedrijf keert geen dividend uit.

De ISIN van Nkarta is US65487U1088.

Het WKN van Nkarta is A2P797.

De ticker van Nkarta is NKTX.

Binnen de laatste 12 maanden betaalde Nkarta een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Nkarta naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Nkarta is momenteel .

Nkarta betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Nkarta betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Nkarta wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Nkarta van 13-9-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 13-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 13-9-2024.

In het jaar 2023 heeft Nkarta 0 USD aan dividenden uitgekeerd.

De dividenden van Nkarta worden in USD uitgekeerd.